高级检索
当前位置: 首页 > 详情页

RETRACTED: The correlation of plasma microRNA-200 family expressions with risk and disease severity of lupus nephritis (Retracted article. See vol. 25, pg. 3641, 2021)

| 认领 | 导出 |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Shanghai Jiao Tong Univ, Sch Med, Tongren Hosp, Dept TCM, Shanghai, Peoples R China
出处:
ISSN:

关键词: MiR-200 family Lupus nephritis Risk Severity Bio-marker

摘要:
OBJECTIVE: To investigate whether plasma microRNA-200 family expressions could serve as diagnostic biomarkers in patients with lupus nephritis (LN), and their association with disease severity. PATIENTS AND METHODS: 101 adult LN patients and 100 adult health volunteers were recruited in our study. A blood sample was obtained from all participants, and total RNA was extracted from plasma. Real-time PCR was performed to evaluate the relative expression of microRNA (miRNA). SLE disease activity index (SLEDAI) score was calculated to evaluate the overall disease severity. RESULTS: Plasma miR-200b-5p, miR-141-5p, and miR-200c-5p expressions were decreased in LN patients compared to that in health controls (HCs). Multivariate logistic regression model revealed that plasma miR-200b-5p, miR141-5p, and miR-200c-5p expressions were independent protective factors for predicting LN states. Receiver operating curve (ROC) was conducted to assess the diagnostic value of miR-200b-5p, miR-141-5p, and miR-200c-5p, and they revealed good diagnostic value with the area under curve (AUC) of 0.748, 0.748, 0.723, respectively. When miR-200b-5p, miR-141-5p, and miR-200c-5p are combined each other, the AUC increased to 0.936, suggesting a great diagnostic value of LN. Also, plasma miR-141-5p was observed to be negatively associated with serum creatinine and SLEDAI score, and the inverse correlations were found of miR-200c-5p with SLEDAI score, as well as miR-200b-3p with proteinuria. CONCLUSIONS: Circulating miR-200b-5p, miR-141-5p, and miR-200c-5p expressions could be served as novel and convincing diagnostic biomarkers for LN.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 4 区 药学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 药学
JCR分区:
出版当年[2016]版:
Q3 PHARMACOLOGY & PHARMACY
最新[2023]版:

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Shanghai Jiao Tong Univ, Sch Med, Tongren Hosp, Dept TCM, Shanghai, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21169 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)